Misoprostol dose-related shivering and pyrexia in the third stage of labour

Objective To select the misoprostol dose to be used in a large multicentre randomised trial comparing misoprostol with oxytocin in the routine managem ent of the third stage of labour. Design Randomised pilot trial, double-blinded viiith the use of double plac ebos. Setting Two of the nine hospitals that will participate in the main multice ntre trial. The hospitals were located in Johannesburg, South Africa and Kh on Kaen, Thailand. Population Women during second stage of labour about to be delivered vaginally. Methods The trial had three arms: misoprostol 400 mu g versus misoprostol 6 00 mu g versus intramuscular oxytocin 10 IU. Each group received an injecti on and three tablets immediately after the birth of the baby. Main outcome measures Shivering and pyrexia rates were the main outcome mea sures. Data on other side effects and characteristics of the third stage of labour were also collected. Side effects were noted as none, mild, moderat e or severe. Results Both shivering and pyrexia (temperature > 38 degrees C) were most c ommon in the 600 mu g misoprostol group (28% and 7.5% for shivering and pyr exia, respectively) compared with 400 pg misoprostol (19% and 2%), and the oxytocin group (12.5% and 3%). The increase in shivering in the misoprostol 600 mu g group was due primarily to a higher rate of moderate shivering. N one of the women had a temperature > 40 degrees C. There were no increases in severe side effects and other adverse events in the misoprostol 600 mu g group. Conclusions When used in the management of the third stage of labour oral m isoprostol is associated with an increase in the rate of moderate shivering and pyrexia which seems to be dose-related. Based on the results of this p ilot trial, the Steering Committee has decided to use 600 mu g misoprostol in the main trial, comparing it with oxytocin, in order to achieve higher e ffectiveness.